FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:934-936 February 26, 2004 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Sands, B. E. PubMed Citation

Among the many complications of Crohn's disease, the development of fistulas is one of the most distressing to patients because it decreases their quality of life and one of the most frustrating to physicians because of the dishearteningly high rate of management failure. Review articles offer complex clinical algorithms and long lists of therapeutic options for fistulizing Crohn's disease, ranging from antibiotics, immunomodulators, and biologic and miscellaneous agents to complementary, but seldom definitive, surgical interventions.¹ Long experience has shown that the more diversified the therapeutic options are, the less likely it is that any one of them will work well, . . . [Full Text of this Article]

Source Information

From Case Western Reserve University School of Medicine, Cleveland.

This article has been cited by other articles:

• Biancone, L, Orlando, A, Kohn, A, Colombo, E, Sostegni, R, Angelucci, E, Rizzello, F, Castiglione, F, Benazzato, L, Papi, C, Meucci, G, Riegler, G, Petruzziello, C, Mocciaro, F, Geremia, A, Calabrese, E, Cottone, M, Pallone, F (2006). Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 55: 228-233 [Abstract] [Full Text]  
• McGovern, D P B, Travis, S P L (2005). Smoking status in therapeutic trials in Crohn's disease. Gut 54: 1047-1048 [Full Text]